Galecto Inc. has appointed Sherwin Sattarzadeh as Chief Operating Officer and Dr. Becker Hewes as Chief Medical Officer, effective January 5, 2026. Both executives bring significant hematology and oncology drug development experience to the company as it prepares to advance its lead candidate, DMR-001, into clinical trials.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galecto Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9620383) on January 06, 2026, and is solely responsible for the information contained therein.